Literature DB >> 26887855

Abuse of Gabapentin is Associated with Opioid Addiction.

Leo Bastiaens1, James Galus2, Cherise Mazur2.   

Abstract

The objective of this study was to evaluate the extent of gabapentin misuse in a dually diagnosed correctional population, and to evaluate if this abuse is specific to the presence of an opioid use disorder (OUD). Two-hundred and fifty former inmates, living in a correctional community center, who were referred for a psychiatric evaluation, were asked, through a brief written questionnaire, whether or not they used the following drugs for non-medical use in the past: opiates, gabapentin, buproprion, quetiapine, and fluoxetine. The average age of this population was 37.2 ± 12.1 years (n = 250). Sixty-four percent were male, 72 % were white, 27 % were black, and 1 % was Hispanic. All patients had substance use disorders, the large majority (72 %) to more than one substance. Fifty-eight percent had an opioid use disorder, again mostly in combination with other drugs and/or alcohol. Depressive disorders and attention deficit hyperactivity disorder were the most common psychiatric conditions. Sixty-two percent of patients reported prescription drug misuse of any kind. As expected, a high percent (55 %) reported opiate misuse. No patient reported fluoxetine misuse. Sixteen percent reported having misused gabapentin in the past. Of patients with an opioid use disorder (OUD: n = 145), 26 % endorsed gabapentin abuse while only 4 % of patients without an OUD (n = 105) endorsed the non-medical use of gabapentin. This difference was highly statistically significant (Chi square χ2 = 21.6, p < 0.0001). A growing concern about gabapentin misuse was supported in this study: 26 percent of opiate addicted patients reported illegally obtaining, overusing, or malingering problems to obtain gabapentin. This study highlights the fact that gabapentin abuse appears specific to an opioid addicted population.

Entities:  

Keywords:  Correctional population; Gabapentin abuse; Opioid addiction

Mesh:

Substances:

Year:  2016        PMID: 26887855     DOI: 10.1007/s11126-016-9421-7

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  5 in total

1.  Gabapentin treatment for insomnia associated with alcohol dependence.

Authors:  M Karam-Hage; K J Brower
Journal:  Am J Psychiatry       Date:  2000-01       Impact factor: 18.112

2.  Treatment of social phobia with gabapentin: a placebo-controlled study.

Authors:  A C Pande; J R Davidson; J W Jefferson; C A Janney; D J Katzelnick; R H Weisler; J H Greist; S M Sutherland
Journal:  J Clin Psychopharmacol       Date:  1999-08       Impact factor: 3.153

3.  Gabapentin modifies extracellular opioid peptide content in amygdala: a microdialysis study.

Authors:  L Rocha; R Ondarza-Rovira; N T Maidment
Journal:  Epilepsy Res       Date:  1999-05       Impact factor: 3.045

4.  Placebo-controlled study of gabapentin treatment of panic disorder.

Authors:  A C Pande; M H Pollack; J Crockatt; M Greiner; G Chouinard; R B Lydiard; C B Taylor; S R Dager; T Shiovitz
Journal:  J Clin Psychopharmacol       Date:  2000-08       Impact factor: 3.153

Review 5.  Neurocircuitry of addiction.

Authors:  George F Koob; Nora D Volkow
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

  5 in total
  22 in total

Review 1.  Abuse and Misuse of Pregabalin and Gabapentin.

Authors:  Kirk E Evoy; Megan D Morrison; Stephen R Saklad
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

2.  Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France.

Authors:  Damien Driot; Emilie Jouanjus; Stéphane Oustric; Julie Dupouy; Maryse Lapeyre-Mestre
Journal:  Br J Clin Pharmacol       Date:  2019-03-28       Impact factor: 4.335

3.  Gabapentin Abuse in a Patient with Comorbid Mood and Substance Use Disorders.

Authors:  Oleg V Tcheremissine; Durga Prasad Bestha
Journal:  Innov Clin Neurosci       Date:  2016-08-01

4.  Oxycodone-induced tolerance to respiratory depression: reversal by ethanol, pregabalin and protein kinase C inhibition.

Authors:  Rob Hill; William L Dewey; Eamonn Kelly; Graeme Henderson
Journal:  Br J Pharmacol       Date:  2018-05-07       Impact factor: 8.739

5.  A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky.

Authors:  Rachel Vickers Smith; Elaine M Boland; April M Young; Michelle R Lofwall; Alexa Quiroz; Michele Staton; Jennifer R Havens
Journal:  Psychol Addict Behav       Date:  2017-12-14

6.  Risk to heroin users of polydrug use of pregabalin or gabapentin.

Authors:  Abigail Lyndon; Suzanne Audrey; Claudia Wells; Erica S Burnell; Suzanne Ingle; Rob Hill; Matthew Hickman; Graeme Henderson
Journal:  Addiction       Date:  2017-05-15       Impact factor: 6.526

7.  Factors Associated with Gabapentin Misuse among People Who Inject Drugs in Appalachian Kentucky.

Authors:  Mance E Buttram; Hilary L Surratt
Journal:  Subst Use Misuse       Date:  2020-09-11       Impact factor: 2.164

Review 8.  Gabapentin for the treatment of alcohol use disorder.

Authors:  Barbara J Mason; Susan Quello; Farhad Shadan
Journal:  Expert Opin Investig Drugs       Date:  2017-12-23       Impact factor: 6.206

9.  Prescribed and non-prescribed gabapentin use among persons seeking inpatient opioid detoxification.

Authors:  Michael D Stein; Shannon R Kenney; Bradley J Anderson; Micah T Conti; Genie L Bailey
Journal:  J Subst Abuse Treat       Date:  2019-12-13

10.  Global patterns of opioid use and dependence: harms to populations, interventions, and future action.

Authors:  Louisa Degenhardt; Jason Grebely; Jack Stone; Matthew Hickman; Peter Vickerman; Brandon D L Marshall; Julie Bruneau; Frederick L Altice; Graeme Henderson; Afarin Rahimi-Movaghar; Sarah Larney
Journal:  Lancet       Date:  2019-10-23       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.